Browsing by Subject "Costs and cost analysis"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Diagnosis and Management of Type 2 Diabetic Kidney Disease
    (American Society of Nephrology, 2017-08-07) Doshi, Simit M.; Friedman, Allon N.; Medicine, School of Medicine
    Type 2 diabetic kidney disease (DKD) is the most common cause of CKD and ESRD worldwide, and carries with it enormous human and societal costs. The goal of this review is to provide an update on the diagnosis and management of DKD based on a comprehensive review of the medical literature. Topics addressed include the evolving presentation of DKD, clinical differentiation of DKD from non-DKD, a state-of-the-art evaluation of current treatment strategies, and promising emerging treatments. It is expected that the review will help clinicians to diagnose and manage patients with DKD.
  • Thumbnail Image
    Item
    Strategies to Reduce Low-Value Cardiovascular Care: A Scientific Statement From the American Heart Association
    (American Heart Association, 2022) Kini, Vinay; Breathett, Khadijah; Groeneveld, Peter W.; Ho, P. Michael; Nallamothu, Brahmajee K.; Peterson, Pamela N.; Rush, Pam; Wang, Tracy Y.; Zeitler, Emily P.; Borden, William B.; American Heart Association Council on Quality of Care and Outcomes Research; Medicine, School of Medicine
    Low-value health care services that provide little or no benefit to patients are common, potentially harmful, and costly. Nearly half of the patients in the United States will receive at least 1 low-value test or procedure annually, creating risk of avoidable complications from subsequent cascades of care and excess costs to patients and society. Reducing low-value care is of particular importance to cardiovascular health given the high prevalence and costs of cardiovascular disease in the United States. This scientific statement describes the current scope and impact of low-value cardiovascular care; reviews existing literature on patient-, clinician-, health system-, payer-, and policy-level interventions to reduce low-value care; proposes solutions to achieve meaningful and equitable reductions in low-value care; and suggests areas for future research priorities.
  • Thumbnail Image
    Item
    The Worldwide Economic Impact of Neurogenic Bladder
    (Springer, 2015-12) Flack, Chandra; Powell, C.R.; Department of Urology, IU School of Medicine
    Costs of neurogenic bladder vary widely and depend on a number of factors including severity of disease, symptomatology, patient insurance, and devices required. Recognition of how each treatment strategy will impact the patient financially could help guide selection of treatment as well as improve compliance with the chosen regimen. We have attempted to provide an overview of long term cost considerations for the neurogenic bladder patient. Armed with this information, the practitioner can better help the patient select a bladder care regimen that balances the desire to both minimize symptoms now and preserve urinary tract integrity for the future, yet still remain cost effective.